Author/Authors :
Saffar, M.J mazandaran university of medical sciences - Bouali-Cina Hospital - Department of Paediatrics, Paediatric Infectious Disease Ward, ايران , Alraza-Amiri, M. mazandaran university of medical sciences - Bouali-Cina Hospital - Department of Paediatrics, Paediatric Infectious Disease Ward, ايران , Ajami, A. mazandaran university of medical sciences - Bouali-Cina Hospital - Department of Paediatrics, Paediatric Infectious Disease Ward, ايران , Baba-Mahmoodi, F. mazandaran university of medical sciences - Bouali-Cina Hospital - Department of Paediatrics, Paediatric Infectious Disease Ward, ايران , Khalilian, A.R. mazandaran university of medical sciences - Bouali-Cina Hospital - Department of Paediatrics, Paediatric Infectious Disease Ward, ايران , Vahidshahi, C. mazandaran university of medical sciences - Bouali-Cina Hospital - Department of Paediatrics, Paediatric Infectious Disease Ward, ايران , Shamsizadeh, A. mazandaran university of medical sciences - Bouali-Cina Hospital - Department of Paediatrics, Paediatric Infectious Disease Ward, ايران
Abstract :
We evaluated the seroprevalence of measles antibody and response to measles reimmunization in 590 previously vaccinated adolescents and young adults; 263 were seronegative. To differentiate between primary and secondary vaccine failure, anti-measles IgM and IgG titres were assessed again 2–4 weeks after revaccination in 144 (105 seronegative, 39 seropositive) individuals: 75 seronegative participants responded to revaccination anamnestically (P 0.001) and developed immunity, 11 also showed IgM response (probably primary vaccine failure); 38 seropositive participants remained seroprotected without significant increase in antibody titre (P = 0.577). Primary vaccine failure was 4.7%; secondary vaccine failure was 27.1%. After revaccination, 87.3% were seroprotected.
